More recently, the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667), showed efficacy in advanced MTC, but molecular testing for germline or somatic RET mutations is essential [29]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.